Compare Nvidia Corp (NVDA) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nvidia Corp vs TransMedics Group Inc — how do they compare? Nvidia Corp trades at $223.11 (market cap $5.27T), while TransMedics Group Inc trades at $87.58 (market cap $3.10B). The key difference: Nvidia Corp is far larger — about 1700× TransMedics Group Inc's market cap, and Nvidia Corp pays a 0.46% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| NVDA | TMDX | |
|---|---|---|
Market Cap | $5.27T | $3.10B |
Sector | Technology | Technology |
52-Week High | $235.75 | $150.42 |
52-Week Low | $165.17 | $61.99 |
Enterprise Value | $5.20T | $3.49B |
Dividend Yield | 0.46% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVIDIA (NVDA) trades at $223.75, up 2.85% today, near its R3 resistance of $224. The stock shows strong fundamentals with revenue surging to $130.50B in 2025 and net income at $72.88B, driven by AI chip demand. Recent earnings beats and a bullish analyst consensus of 75% buy ratings support momentum, though RSI levels hint at overbought conditions.
Outlook remains positive with a $325.86 price target, but risks include peak AI spending concerns and competition. Growth is sustainable if execution continues, yet volatility from macroeconomic factors warrants caution for new positions.
TransMedics Group (TMDX) trades at $87.42, down 1.12% on the day, with a bullish technical outlook from moving averages but bearish oscillators signaling potential overbought conditions. The company reported mixed Q2 2026 results, missing earnings estimates with EPS of $0.44 versus $0.50 expected, while revenue growth remains robust. Recent news highlights an ongoing investigation into fiduciary duties by directors, adding uncertainty.
The stock presents a cautious opportunity with strong analyst support (69% buy ratings) and a consensus price target of $99.57, implying upside, but risks include earnings volatility, margin pressures, and legal scrutiny. Fundamentals show solid profitability with a 22.69% net margin, though valuation multiples like P/E of 23.15 suggest premium pricing relative to historical norms.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nvidia Corp
NVIDIA Corporation designs, develops, and markets three dimensional (3D) graphics processors and related software. The Company offers products that provides interactive 3D graphics to the mainstream personal computer market.
Read more on NVDA →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
